Trial Profile

A Multicenter, Prospective, Observational Study to Evaluate Effectiveness and Safety of Fixed-dose Combinations of Fimasartan/Amlodipine or Fimasartan/Amlodipine/Hydrochlorothiazide in Essential Hypertensive Patients

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 24 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amlodipine/fimasartan (Primary) ; Amlodipine/fimasartan/hydrochlorothiazide (Primary)
Indications Essential hypertension
Focus Therapeutic Use
Sponsors Boryung Pharmaceutical

21 May 2024 Planned End Date changed from 1 Oct 2026 to 1 Jun 2026.
21 May 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Jun 2026.
07 Jul 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com